Profil
Heng Hsin Tang served as a Non-Executive Director at TBG Diagnostics Ltd.
from 2014 to 2015 and as the Managing Director at PharmaSynth Pty Ltd.
in 2014-2015.
Mr. Tang received an undergraduate degree and an MBA from The University of Queensland.
Ehemalige bekannte Positionen von Heng Hsin Tang
| Unternehmen | Position | Ende |
|---|---|---|
| TBG DIAGNOSTICS LIMITED | Vorstandsvorsitzender | 28.07.2014 |
PharmaSynth Pty Ltd.
 PharmaSynth Pty Ltd. Pharmaceuticals: MajorHealth Technology PharmaSynth Pty Ltd. develops drugs and provides contract manufacturing services. The firm’s services include biopharmaceutical contract manufacturing, GMP manufacture of recombinant proteins and vaccines, microbial products, small molecule synthesis for human and veterinary use, synthetic organic chemistry, production of GMP material for pre-clinical studies and clinical trial material batches for Phase 1, 2 and 3 clinical studies. The company was founded in 2009 and is headquartered in Darra, Australia. | Vorstandsvorsitzender | 16.03.2015 |
Ausbildung von Heng Hsin Tang
| The University of Queensland | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
TBG Diagnostics Ltd.
 TBG Diagnostics Ltd. Pharmaceuticals: MajorHealth Technology TBG Diagnostics Ltd. engages in the research, development, and manufacture of biopharmaceuticals. It operates through the InVitro Diagnostics segment, which involves in the research of biological drugs and the retail and wholesale of veterinary drugs. The company was founded on September 26, 1989 and is headquartered in Melbourne, Australia. | Health Technology |
PharmaSynth Pty Ltd.
PharmaSynth Pty Ltd. Pharmaceuticals: MajorHealth Technology PharmaSynth Pty Ltd. develops drugs and provides contract manufacturing services. The firm’s services include biopharmaceutical contract manufacturing, GMP manufacture of recombinant proteins and vaccines, microbial products, small molecule synthesis for human and veterinary use, synthetic organic chemistry, production of GMP material for pre-clinical studies and clinical trial material batches for Phase 1, 2 and 3 clinical studies. The company was founded in 2009 and is headquartered in Darra, Australia. | Health Technology |
